Temsirolimus is an intravenously administered small molecule inhibitor of mTOR and was explored as single-agent therapy at up to 75 mg weekly in a phase 2 study that enrolled 37 patients with recurrent or refractory PCNSL [35]. Here, MTOR is linked to primary central nervous system lymphoma.